The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer


Autoři: Song Zheng aff001;  Shaoqin Jiang aff001;  Zhenlin Chen aff001;  Zhangcheng Huang aff001;  Wenzhen Shi aff001;  Bingqiao Liu aff001;  Yue Xu aff001;  Yinan Guo aff002;  Huijie Yang aff001;  Mengqiang Li aff001
Působiště autorů: Laboratory of Urology, Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, China aff001;  Department of Nursing, Laboratory of Urology, Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, Fujian, China aff002
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0218645

Souhrn

Prostate biopsies are frequently performed to screen for prostate cancer (PCa) with complications such as infections and bleeding. To reduce unnecessary biopsies, here we designed an improved predictive model of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen (PSA) concentrations for diagnosing PCa and risk stratification. Multiparametric MRI administered to 422 consecutive patients before initial transrectal ultrasonography-guided 13-core prostate biopsies from January 2012 to March 2018 at Fujian Medical University Union Hospital. Univariate and multivariate logistic regression analyses and determination of the area under the curve (AUC) of the receiver operating characteristic (ROC) curve was performed to evaluate and integrate the predictors of PCa and high-risk prostate cancer (HR-PCa). The detection rates of PCa was 43.84% (185/422). And the detection rates of HR-PCa was 71.35% (132/185) in PCa patients. Multivariate analysis revealed that prostate volume(PV), PSA density(PSAD), transitional zone volume(TZV), PSA density of the transitional zone(PSADTZ), and MR were independent predictors of PCa and HR-PCa. PSA, peripheral zone volume(PZV) and PSA density of the peripheral zone(PSADPZ) were independent predictors of PCa but not HR-PCa. The AUC of our best predictive model including PSA + PV + PSAD + MR + TZV or PSA + PV + PSAD + MR + PZV was 0.906 for PCa. The AUC of the best predictive model of PV + PSAD + MR + TZV was 0.893 for HR-PCa. In conclusion, our results will likely improve the detection rate of prostate cancer, avoiding unnecessary prostate biopsies, and for evaluating risk stratification.

Klíčová slova:

Biopsy – Cancer detection and diagnosis – Magnetic resonance imaging – Prostate cancer – Prostate gland – Regression analysis


Zdroje

1. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124(13):2785–800. doi: 10.1002/cncr.31551 29786848

2. van den Bergh R.C.N. Mottet N., Briers E., Bourke L., Cornford P., De Santis M., Gillessen S., Govorov A.. EAU—ESTRO—ESUR—SIOG Guidelines on Prostate Cancer. 2018.

3. Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J, et al. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: a cancer journal for clinicians. 2016;66(2):96–114.

4. Huang Y, Cheng G, Liu B, Shao P, Qin C, Li J, et al. A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients. BMC urology. 2014;14(undefined):8.

5. Shen P, Zhao J, Sun G, Chen N, Zhang X, Gui H, et al. The roles of prostate-specific antigen (PSA) density, prostate volume, and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng/mL. Andrology. 2017;5(3):548–55. doi: 10.1111/andr.12322 28409907

6. Zhuo C., Liang L., Ying M., Li Q., Li D., Li Y., et al. Laparoscopic Low Anterior Resection and Eversion Technique Combined With a Nondog Ear Anastomosis for Mid- and Distal Rectal Neoplasms: A Preliminary and Feasibility Study. Medicine. 2015;94(50):e2285. Epub 2015/12/20. doi: 10.1097/MD.0000000000002285 26683958; PubMed Central PMCID: PMC5058930 decision to publish, or preparation of the manuscript. The authors declare that they have no conflict of interest.

7. MacAskill F, Lee SM, Eldred-Evans D, Wulaningsih W, Popert R, Wolfe K, et al. Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes. International urology and nephrology. 2017;49(8):1335–42. doi: 10.1007/s11255-017-1609-8 28477301

8. Zhang Y, Xin Y Li Q, Lv W. Differentiating prostate cancer from benign prostatic hyperplasia using PSAD based on machine learning: Single-center retrospective study in China. IEEE/ACM Trans Comput Biol Bioinform. 2018.

9. Yacoub JH, Oto A. MR Imaging of Prostate Zonal Anatomy. Radiologic clinics of North America. 2018;56(2):197–209. doi: 10.1016/j.rcl.2017.10.003 29420976

10. Erbersdobler A Augustin H, Hammerer PG, Graefen M, Huland H,. Prostate cancers in the transition zone: Part 2; clinical aspects. BJU Int. 2004.

11. Fu Q, Yao DH, Jiang YQ. Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer. Zhonghua nan ke xue = National journal of andrology. 2002;8(6):411–3. 12593013

12. Castro HAS, Iared W, Santos JEM, Solha RS, Shigueoka DC, Ajzen SA. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL. International braz j urol: official journal of the Brazilian Society of Urology. 2018;44(4):709–16.

13. Tanaka N, Fujimoto K, Chihara Y, Torimoto M, Hirao Y, Konishi N, et al. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels. Prostate cancer and prostatic diseases. 2007;10(3):274–8. doi: 10.1038/sj.pcan.4500957 17339878

14. O'Mahoney P. R., Trencheva K., Zhuo C., Shukla P. J., Lee S. W., Sonoda T., et al. Systematic Video Documentation in Laparoscopic Colon Surgery Using a Checklist: A Feasibility and Compliance Pilot Study. Journal of laparoendoscopic & advanced surgical techniques Part A. 2015;25(9):737–43. Epub 2015/09/17. doi: 10.1089/lap.2014.0603 26375772.

15. Nathan MS, Seenivasagam K, Mei Q, Wickham JE, Miller RA. Transrectal ultrasonography: why are estimates of prostate volume and dimension so inaccurate? British journal of urology. 1996;77(3):401–7. doi: 10.1046/j.1464-410x.1996.90214.x 8814846

16. Rahmouni A, Yang A, Tempany CM, Frenkel T, Epstein J, Walsh P, et al. Accuracy of in-vivo assessment of prostatic volume by MRI and transrectal ultrasonography. Journal of computer assisted tomography. 1992;16(6):935–40. doi: 10.1097/00004728-199211000-00020 1385499

17. Chang Y, Chen R, Yang Q, Gao X, Xu C, Lu J, et al. Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality. Oncotarget. 2017;8(21):34836–43. doi: 10.18632/oncotarget.16753 28422738

18. Fedorov A, Vangel MG, Tempany CM, Fennessy FM. Multiparametric Magnetic Resonance Imaging of the Prostate: Repeatability of Volume and Apparent Diffusion Coefficient Quantification. Investigative radiology. 2017;52(9):538–46. doi: 10.1097/RLI.0000000000000382 28463931

19. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. 1992;147(null):815–6.

20. Giannarini G., Scott C. A., Moro U., Pertoldi B., Beltrami C. A., Selli C. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer? Urol Oncol. 2008;26(4):353–60. Epub 2008/03/28. doi: 10.1016/j.urolonc.2007.04.002 18367100.

21. Nowroozi M., Ayati M., Jamshidian H., Arbab A., Ghorbani H., Amini E., et al. Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men. Nephrourol Mon. 2015;7(2):e26752. Epub 2015/03/31. doi: 10.5812/numonthly.26752 25821749; PubMed Central PMCID: PMC4360524.

22. Tang P., Du W., Xie K., Deng X., Fu J., Chen H., et al. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0–10.0 and 10.1–20.0 ng/ml in Chinese men. Urol Oncol. 2013;31(6):744–8. Epub 2011/08/27. doi: 10.1016/j.urolonc.2011.06.012 21868261.

23. Xie S. W., Wang Y. Q., Dong B. J., Xia J. G., Li H. L., Zhang S. J., et al. A Nomogram Based on a TRUS Five-Grade Scoring System for the Prediction of Prostate Cancer and High Grade Prostate Cancer at Initial TRUS-Guided Biopsy. J Cancer. 2018;9(23):4382–90. Epub 2018/12/07. doi: 10.7150/jca.27344 30519343; PubMed Central PMCID: PMC6277649.

24. Ujike T., Uemura M., Kawashima A., Nagahara A., Fujita K., Miyagawa Y., et al. A novel model to predict positive prostate biopsy based on serum androgen level. Endocr Relat Cancer. 2018;25(1):59–67. Epub 2017/10/20. doi: 10.1530/ERC-17-0134 29046289; PubMed Central PMCID: PMC5744473.

25. Koie T., Mitsuzuka K., Yoneyama T., Narita S., Kawamura S., Kaiho Y., et al. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy. Int J Clin Oncol. 2015;20(1):176–81. Epub 2014/04/29. doi: 10.1007/s10147-014-0696-0 24771079.

26. Jeong I. G., Lim J. H., Hwang S. S., Kim S. C., You D., Hong J. H., et al. Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy. Prostate Int. 2013;1(2):69–75. Epub 2013/11/14. doi: 10.12954/PI.12008 24223405; PubMed Central PMCID: PMC3814113.


Článek vyšel v časopise

PLOS One


2019 Číslo 11